Phosphodiesterase 5 inhibitors and erectile dysfunction

Bibliography

• Melman A, Gingel AC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999;161:5-11
   PubMed Web of Science ®Google Scholar
• Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med 2007;4:57-65
   PubMed Web of Science ®Google Scholar
• Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12:305-11
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84
   PubMed Web of Science ®Google Scholar
• Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6
   PubMed Web of Science ®Google Scholar
• Bella AJ, Brock GB. Intracavernous pharmacotherapy for erectile dysfunction. Endocrine 2004;23:149-55
   PubMed Web of Science ®Google Scholar
• Levine LA, Dimitriou RJ. Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001;28:335-41
   PubMed Web of Science ®Google Scholar
• McCullough AR. Four-year review of sildenafil citrate. Rev Urol 2002;4(Suppl):26-38
   PubMedGoogle Scholar
• Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 2005;6:75-84
   PubMed Web of Science ®Google Scholar
• Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother 2007;8:965-74
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. Int J Clin Pract 2007;61:1547-54
   PubMed Web of Science ®Google Scholar
• Jain S, Terry TR. Penile prosthetic surgery and its role in the treatment of end-stage erectile dysfunction – an update. Ann R Coll Surg Engl 2006;88:343-8
   Google Scholar
• Wessels H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int J Impot Res 2000;12:74-9
   Google Scholar
• Wessels H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides 2005;26:1972-7
   Google Scholar
• Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;8:212-5
   Google Scholar
• Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003;61:464-7
   Google Scholar
• Chitaey K, Bivalacqua TJ, Champion HC. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun 2002;298:427-32
   Google Scholar
• Linder AE, Webb RC, Mills TM, Ying Z, Lewis RW, Teixeira CE. Rho-kinase and RGS-containing RhoGEFs as molecular targets for the treatment of erectile dysfunction. Curr Pharm Des 2005;11:4029-40
   PubMed Web of Science ®Google Scholar
• Moon DG, Byun HS, Kim JJ. A KATP-channel opener as a potential treatment modality for erectile dysfunction. BJU Int 1999;83:837-41
   Google Scholar
• Mills JN, Dall'era JE, Carlsen SN, Koul H, Meacham RB. Gene therapy for erectile dysfunction. Pharmacogenomics 2007;8:979-84
   Google Scholar
• Haning H, Niewohner U, Bischoff E. Phosphodiesterase type 5 (PDE5) inhibitors. Prog Med Chem 2003;41:249-306
   Google Scholar
• Sui Z. Phosphodiesterase-5 inhibitors for male erectile dysfunction. Expert Opin Ther Patents 2003;13:1373-83
   Web of Science ®Google Scholar
• Pfizer Ltd. WO2003038080 (2003)
   Google Scholar
• Pfizer Ltd. WO2004097010 (2004)
   Google Scholar
• Palmer MJ, Bell AS, Fox DANN, et al. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem 2007;7:405-19
   PubMedGoogle Scholar
• Pfizer Ltd. WO2004096810 (2004)
   Google Scholar
• Pfizer Ltd. WO2005049617 (2005)
   Google Scholar
• Pfizer Products, Inc. WO2007054778 (2007)
   Google Scholar
• Pfizer, Inc. WO2006120552 (2006)
   Google Scholar
• Pharmacia & Upjohn Co. LLC. WO2006126081 (2006)
   Google Scholar
• Pharmacia & Upjohn Co. LLC. WO2006126082 (2006)
   Google Scholar
• Pharmacia & Upjohn Co. LLC. WO2006126083 (2006)
   Google Scholar
• Pharmacia & Upjohn Co. LLC. WO2007020521 (2007)
   Google Scholar
• Dong A Pharm. Co., Ltd. WO200027848 (2000)
   Google Scholar
• Doh H, Shin CY, Son M, et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 2002;25:873-8
   PubMed Web of Science ®Google Scholar
• Kim YC, Yoo M, Lee MG. DA-8159 – Udenafil. Drugs Future 2005;30:678-82
   Google Scholar
• Salem EA, Kendirici M, Hellstrom WJ. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006;7:661-9
   PubMedGoogle Scholar
• SK Chemicals Co., Ltd. WO2001060825 (2001)
   Google Scholar
• Paick JS, Choi HK, Kim SC, et al. Efficacy and safety of oral SK3530 in the treatment of men in Korea with erectile dysfunction: a multi-center, randomized, double blind, placebo controlled, fixed dose, parallel group, clinical trial. J Sex Med 2006;3(S5):393
   Google Scholar
• Kotera J, Fujishige K, Michibata H, et al. Characterization and effects of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Pharmacol 2000;60:1333-41
   PubMed Web of Science ®Google Scholar
• Kaufmann JM, Aurora CO, Dietrich JW. Safety and efficacy of avanafil, a new phosphodiesterase type 5 (PDE5) inhibitor for treating erectile dysfunction. J Urol 2006;175(S4):299
   Google Scholar
• Surface Logix, Inc. WO2006089276 (2006)
   Google Scholar
• Prince W, Campbell AS, Tong W, et al. SLx-2102, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol 2006;175(S4):924
   Google Scholar
• Ortho-McNeil Pharmaceutical, Inc. WO2001087882 (2001)
   Google Scholar
• Qui Y, Bhattacharjee S, Kraft P, et al. JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction. Int J Impot Res 2006;18:477-83
   Google Scholar
• Meier D. The Annual Meeting of PDE in Drug Discovery and Development, Cherry Hill; 2005
   Google Scholar
• Bristol-Myers Squibb Co. US20050080079 (2005)
   Google Scholar
• Esteve Labor DR. WO2005013962 (2005)
   Google Scholar
• Laboratorios Del DR, Esteve SA. EP2001652521 (2001)
   Google Scholar
• Laboratorios Del DR, Esteve SA. WO2006069806 (2006)
   Google Scholar
• Chen J, Wollman Y, Chernichovsky T, Iaina A, Sofer M, Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 1999;83:269-71
   PubMed Web of Science ®Google Scholar
• ISIS Pharma GMBH, Schwarz Pharma AG. WO2000010542 (2000)
   Google Scholar
• Encysive Pharmaceuticals. WO2006026395 (2006)
   Google Scholar
• Mayo Foundation for Medical Education and Research. WO2007070426; (2007)
   Google Scholar
• Dula E, Keating W, Siami PF, Edmonds A, O'Neil J, Buttler S. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000;56:130-5
   PubMed Web of Science ®Google Scholar
• Martinez R, Puigvert A, Pomerol JM, Rodriguez-Villalba R. Clinical experience with apomorphine hydrochloride: the first 107 patients. J Urol 2003;170:2352-5
   PubMed Web of Science ®Google Scholar
• Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004;16:135-42
   PubMed Web of Science ®Google Scholar
• Pentech Pharmaceuticals, Inc. US20006087362 (2000)
   Google Scholar
• Palatin Technologies, Inc. WO2005117935 (2005)
   Google Scholar
• Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9
   PubMedGoogle Scholar
• Yassin AA, Saad F, Diede HE. Combination therapy with testosterone an tadalafil in hypogonadal patients with erectile dysfunction who do not respond to tadalafil as monotherapy. Blickpunkt Der Mann 2003;2:37-9
   Google Scholar
• Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63
   PubMed Web of Science ®Google Scholar
• Unimed Pharmaceuticals, Inc. WO2004037173 (2004)
   Google Scholar
• Aversa A, Bruzziches R, Pili M, Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-84
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Seftel AD, Rosen RC, et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology 2006;68:689-96
   PubMed Web of Science ®Google Scholar
• New Millennium Pharmaceutical. WO199966933 (1999)
   Google Scholar
• Bayer AG. US6740306 (2002)
   Google Scholar
• Hexal AG. WO2000007596 (2000)
   Google Scholar
• Phoqus Pharmaceuticals Ltd. WO200417976 (2004)
   Google Scholar
• Elan Pharma International Ltd. WO2005013937 (2005)
   Google Scholar
• Teva Pharmaceutical Industries Ltd. WO2006091974; 2006
   Google Scholar
• Bayer Healthcare AG. WO2006092207 (2006)
   Google Scholar
• Schering Corp. WO2007002125 (2007)
   Google Scholar
• Pentech Pharmaceuticals, Inc. WO2000054777 (2000)
   Google Scholar
• Wrigley WM Jun CO. WO2002041840 (2002)
   Google Scholar
• Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520
   PubMed Web of Science ®Google Scholar
• Pharmacia & Upjohn. WO2006126081 (2006)
   Google Scholar
• Pharmacia & Upjohn. WO2006126082 (2006)
   Google Scholar
• Pharmacia & Upjohn. WO2006126083 (2006)
   Google Scholar
• Pharmacia & Upjohn. WO2007020521 (2007)
   Google Scholar